top of page

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

decodeMR Team
Sep 4
1 min read

03/09/2026











FDA granted Fast Track Designation to YUTREPIA® for the treatment of Raynaud's phenomenon associated with systemic sclerosis. (Ref)


Liquidia Corporation announced that the US FDA had granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).


  • The company planned to initiate Ph2a, RE-WARM/ NCT07748000 a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026.


  • RE-WARM is designed to characterize the safety and pharmacodynamics of YUTREPIA in pts with SSc-RP.


  • The study will also evaluate whether treatment reduces the number, severity and impact of RP attacks.


  • The study is expected to begin in October 2026, with primary completion targeted for February 2027.



bottom of page